Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors.
Bear AS, Nadler RB, O'Hara MH, Stanton KL, Xu C, Saporito RJ, Rech AJ, Baroja ML, Blanchard T, Elliott MH, Ford MJ, Jones R, Patel S, Brennan A, O'Neil Z, Powell DJ Jr, Vonderheide RH, Linette GP, Carreno BM.
Bear AS, et al.
J Clin Invest. 2024 Sep 17;134(21):e175790. doi: 10.1172/JCI175790.
J Clin Invest. 2024.
PMID: 39287991
Free PMC article.
Clinical Trial.